Project Grant R21AI192808
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Michigan a Project Grant of $677,822 under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of June 2, 2026 and completion date of May 31, 2031. This research initiative aims to advance methodologies for estimating population immunity to Coccidioides fungus and identifying exposures associated with prior infection in the U.S....
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $438,038 to the Regents of the University of California, Berkeley, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period running from July 15, 2025 through June 30, 2027. This Project Grant funds a molecular research initiative investigating the regulation of infectious spore formation in Coccidioides posadasii, the fungal pathogen...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $414,368 to the University of California, Davis under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 23, 2025, with a completion date of June 30, 2027. This award funds research investigating the molecular mechanisms underlying persistent effects of early life exposure to aeroallergens and air pollution on lung function and remodeling. Using...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $787,837 to the Regents of the University of California, San Francisco (UCSF) under the Allergy and Infectious Diseases Research program (CFDA 93.855) Project Grant, effective April 10, 2026, with a completion date of March 31, 2031. This five-year initiative will develop and apply advanced computational and statistical tools to assess the risk that infectious diseases with episodic transmission...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arizona a Project Grant of $3,075,549 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 28, 2025, with a completion date of June 30, 2029. This research initiative investigates airway innate immune responses to Coccidioides infection, a serious fungal disease commonly known as valley fever that is expanding geographically across the United States. The research focuses on...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $3.19 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of June 30, 2029. This grant funds investigator-initiated biomedical research examining the roles and regulation of tissue-resident CD8 T cells during persistent viral infection, utilizing the lymphocytic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arizona a $3.1 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective June 5, 2026, through May 31, 2030. This research initiative focuses on the identification and characterization of novel antifungal compounds targeting dihydroorotate dehydrogenase (DHODH) in Cryptococcus neoformans and Cryptococcus gattii. The project...
- Federal Project Grant Award Summary The University of California, San Diego received a $449,578 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of February 1, 2026 and completion date of January 31, 2031. This grant funds investigator-initiated biomedical research exploring the role of lytic polysaccharide monooxygenases (LPMOs), specifically chitin-binding protein...
- Federal Grant Award Summary Arizona State University received a $429,997 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period June 12, 2026, through May 31, 2028. The award funds research to engineer inducible morphotype switching control in Mycobacterium abscessus (MABS), an antibiotic-resistant nontuberculous mycobacterium (NTM) responsible for rising infections and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $647,181 Project Grant to the University of California, Merced, effective February 1, 2026, through January 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award supports investigator-initiated biomedical research focused on elucidating the regulatory mechanisms governing inflammasome assembly and activity. Inflammasomes are multiprotein complexes...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $420,228 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 5, 2026, with a completion date of May 31, 2028. This secondary data analysis study will examine the relationship between dust exposure and coccidioidomycosis incidence in Arizona using a novel database of spatiotemporally refined dust concentration estimates and over 126,000 reported coccidioidomycosis cases from 2005 to 2022. The research will quantify the effects of daily ambient dust exposure on disease incidence, assess the impact of extreme dust events on disease outbreaks, and identify vulnerable populations—particularly those characterized by low income, poor housing quality, and racial/ethnic minority status—most susceptible to dust-related infection risk. This research directly addresses a critical public health gap in understanding environmental drivers of coccidioidomycosis, a fungal infection that accounts for nearly one-third of community-acquired pneumonia cases in Arizona and represents approximately two-thirds of all U.S. cases. With reported cases doubling from 2013 to 2021 and 2019 cases alone estimated to cost $736 million in lifetime expenses, the project will generate evidence-based knowledge to inform public health interventions and policy responses to this growing infectious disease burden in the southwestern United States.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $420.2k | 6/5/26 |